Aberrations in these three genes are key drivers of therapy resistance in prostate cancer and associated with poorer overall survival, while the incidence of loss of cytoplasmic PTEN protein is doubled in intraductal carcinomas with fair 84% compared to acinar carcinoma, estimated between 9% and 40% [25,26,27]. Here, PTEN is linked to prostate carcinoma.